Regulatory T cells participate in the recovery of ischemic stroke patients.
Early neurological deterioration
Interleukin-10
Ischemic stroke
Neuroinflammation
Regulatory T cells
Risk factors
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
28 Feb 2020
28 Feb 2020
Historique:
received:
04
10
2019
accepted:
19
02
2020
entrez:
1
3
2020
pubmed:
1
3
2020
medline:
24
7
2020
Statut:
epublish
Résumé
Recent preclinical studies have shown that regulatory T cells (Treg) play a key role in the immune response after ischemic stroke (IS). However, the role of Treg in human acute IS has been poorly investigated. Our aim was to study the relationship between circulating Treg and outcome in human IS patients. A total of 204 IS patients and 22 control subjects were recruited. The main study variable was good functional outcome at 3 months (modified Rankin scale ≤2) considering infarct volume, Early Neurological Deterioration (END) and risk of infections as secondary variables. The percentage of circulating Treg was measured at admission, 48, 72 h and at day 7 after stroke onset. Circulating Treg levels were higher in IS patients compared to control subjects. Treg at 48 h were independently associated with good functional outcome (OR, 3.5; CI: 1.9-7.8) after adjusting by confounding factors. Patients with lower Treg at 48 h showed higher frequency of END and risk of infections. In addition, a negative correlation was found between circulating Treg at 48 h (r = - 0.414) and 72 h (r = - 0.418) and infarct volume. These findings suggest that Treg may participate in the recovery of IS patients. Therefore, Treg may be considered a potential therapeutic target in acute ischemic stroke.
Sections du résumé
BACKGROUND
BACKGROUND
Recent preclinical studies have shown that regulatory T cells (Treg) play a key role in the immune response after ischemic stroke (IS). However, the role of Treg in human acute IS has been poorly investigated. Our aim was to study the relationship between circulating Treg and outcome in human IS patients.
METHODS
METHODS
A total of 204 IS patients and 22 control subjects were recruited. The main study variable was good functional outcome at 3 months (modified Rankin scale ≤2) considering infarct volume, Early Neurological Deterioration (END) and risk of infections as secondary variables. The percentage of circulating Treg was measured at admission, 48, 72 h and at day 7 after stroke onset.
RESULTS
RESULTS
Circulating Treg levels were higher in IS patients compared to control subjects. Treg at 48 h were independently associated with good functional outcome (OR, 3.5; CI: 1.9-7.8) after adjusting by confounding factors. Patients with lower Treg at 48 h showed higher frequency of END and risk of infections. In addition, a negative correlation was found between circulating Treg at 48 h (r = - 0.414) and 72 h (r = - 0.418) and infarct volume.
CONCLUSIONS
CONCLUSIONS
These findings suggest that Treg may participate in the recovery of IS patients. Therefore, Treg may be considered a potential therapeutic target in acute ischemic stroke.
Identifiants
pubmed: 32111174
doi: 10.1186/s12883-020-01648-w
pii: 10.1186/s12883-020-01648-w
pmc: PMC7048127
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68Subventions
Organisme : Ministerio de Economía y Competitividad
ID : SAF2014-56336-R and SAF2017-84267-R
Organisme : Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia
ID : GRC2014/027
Organisme : Instituto de Salud Carlos III
ID : PIE13/00024; PI17/01103
Organisme : Instituto de Salud Carlos III
ID : RETICS-INVICTUS-PLUS (RD16/0019)
Organisme : Instituto de Salud Carlos III
ID : CP14/00154
Organisme : Instituto de Salud Carlos III
ID : CPII17/00027
Organisme : Instituto de Salud Carlos III
ID : IFI15/00111
Organisme : Instituto de Salud Carlos III
ID : IN606A-2018/031
Références
Cell Mol Life Sci. 2009 Aug;66(16):2603-22
pubmed: 19390784
Curr Opin Neurol. 2008 Jun;21(3):353-7
pubmed: 18451722
PLoS One. 2008 Sep 08;3(9):e3161
pubmed: 18776930
J Neurol Sci. 1999 Dec 15;171(2):115-20
pubmed: 10581377
Stroke. 2006 Feb;37(2):461-5
pubmed: 16385093
J Neuroimmunol. 2009 Jan 3;206(1-2):112-7
pubmed: 19058859
Ann N Y Acad Sci. 2010 Oct;1207:143-8
pubmed: 20955437
J Cell Mol Med. 2014 Aug;18(8):1571-9
pubmed: 24889329
Neurology. 2003 Feb 25;60(4):620-5
pubmed: 12601102
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):2000-4
pubmed: 22628434
Stroke. 1996 Mar;27(3):415-20
pubmed: 8610305
Neuroscience. 2009 Feb 6;158(3):1174-83
pubmed: 18619524
Neurosci Lett. 1998 Jul 31;251(3):189-92
pubmed: 9726375
J Exp Med. 2006 Jul 10;203(7):1693-700
pubmed: 16818676
Prog Cardiovasc Dis. 1999 Nov-Dec;42(3):209-16
pubmed: 10598921
Lancet. 2008 Oct 11;372(9646):1303-9
pubmed: 18790527
BMC Neurol. 2013 Jun 17;13:62
pubmed: 23773291
Nat Med. 2009 Feb;15(2):192-9
pubmed: 19169263
BMC Neurol. 2018 Oct 3;18(1):164
pubmed: 30285659
Stroke. 2013 Dec;44(12):3509-15
pubmed: 24092548
J Neuroimmunol. 2007 Mar;184(1-2):53-68
pubmed: 17188755
Stroke. 2015 Jan;46(1):212-20
pubmed: 25378432
Pharmacol Rev. 2000 Dec;52(4):595-638
pubmed: 11121511
Int J Clin Exp Pathol. 2013 May 15;6(6):1015-27
pubmed: 23696918
Neuroimmunomodulation. 2010;17(4):223-8
pubmed: 20203528
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Stroke. 2003 Mar;34(3):671-5
pubmed: 12624290
Neurologia. 2014 Mar;29(2):102-22
pubmed: 22152803
Eur J Anaesthesiol. 1996 May;13(3):247-68
pubmed: 8737117
Arch Intern Med. 2004 Sep 13;164(16):1761-8
pubmed: 15364669
Clin Chim Acta. 2013 Apr 18;419:136-8
pubmed: 23438682
J Neuroimaging. 2012 Apr;22(2):155-9
pubmed: 21447023
Neurol Sci. 2001 Aug;22(4):289-96
pubmed: 11808851
Stroke. 2015 May;46(5):1422-30
pubmed: 25791715
J Neuroimmunol. 2012 Feb 29;243(1-2):89-94
pubmed: 22261543
Clin Immunol. 2011 Oct;141(1):111-20
pubmed: 21802372
Infect Disord Drug Targets. 2010 Apr;10(2):91-7
pubmed: 20166972
Arq Neuropsiquiatr. 2013 Nov;71(11):846-51
pubmed: 24394869
Stroke. 2007 Mar;38(3):1097-103
pubmed: 17255542
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
J Cereb Blood Flow Metab. 2013 Jan;33(1):37-47
pubmed: 22968321
J Exp Med. 2006 Jul 10;203(7):1701-11
pubmed: 16818678
Nat Med. 2004 Aug;10(8):801-5
pubmed: 15286781
Stroke. 2009 Oct;40(10):3226-32
pubmed: 19661470
Stroke. 2011 Dec;42(12):3580-6
pubmed: 21960584
Ann Neurol. 2013 Sep;74(3):458-71
pubmed: 23674483
Clin Dev Immunol. 2013;2013:689827
pubmed: 23983771
Stroke. 2000 Jun;31(6):1223-9
pubmed: 10835436
Immunol Today. 1997 Sep;18(9):418-24
pubmed: 9293156
J Neurosci. 2013 Oct 30;33(44):17350-62
pubmed: 24174668